SCHEMBL3182761

SCHEMBL3182761

c1cc(CNCCN2CCCCC2)ccc1CNCCCN1CCOCC1

nearest known ligand 0.68

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CYP2C19 P33261 2/20 0.68
▸ CYP3A4 P08684 1/20 0.68
▸ CYP2D6 P10635 1/20 0.68
▸ DPP7 Q9UHL4 2/20 0.59
▸ APP P05067 1/20 0.54
▸ HRH3 Q9Y5N1 3/20 0.51
▸ KMT2A Q03164 4/20 0.51
▸ MEN1 O00255 3/20 0.51
▸ SCN5A Q14524 1/20 0.50
▸ ALDH1A1 P00352 1/20 0.50
▸ TNKS2 Q9H2K2 1/20 0.49
▸ POLB P06746 1/20 0.49
▸ PARP1 P09874 1/20 0.48
▸ KDM1A O60341 1/20 0.48
▸ MAPT P10636 1/20 0.48
▸ L3MBTL1 Q9Y468 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3175514 0.99 CYP2C19 (0.70) CYP2C19CYP3A4CYP2D6DPP7APP
SCHEMBL3173535 0.99 CYP2C19 (0.70) CYP2C19CYP3A4CYP2D6DPP7APP
SCHEMBL3181015 0.96 CYP2C19 (0.74) CYP2C19CYP3A4CYP2D6DPP7HRH3
SCHEMBL3179723 0.94 CYP2C19 (0.76) CYP2C19CYP3A4CYP2D6DPP7KMT2A
SCHEMBL3175086 0.91 DPP7 (0.70) CYP2C19CYP3A4CYP2D6DPP7APP
SCHEMBL3175221 0.91 CYP2C19 (0.80) CYP2C19CYP3A4CYP2D6KMT2AMEN1
SCHEMBL3176696 0.89 DPP7 (0.72) CYP2C19CYP3A4CYP2D6DPP7KMT2A
SCHEMBL3166127 0.88 CYP2D6 (0.65) CYP2C19CYP3A4CYP2D6DPP7APP
SCHEMBL3185540 0.87 CYP2C19 (0.67) CYP2C19CYP3A4CYP2D6DPP7KMT2A
SCHEMBL5097548 0.87 HRH3 (0.71) HRH3KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100022769-A1 NOVEL POLYNITROGENATED SYSTEMS AS ANTI-HIV AGENTS INSTITUT QUIMIC DE SARRIA CETS (ES) 2010-01-28 — — US claimed
EP-2100890-A1 NOVEL POLYNITROGENATED SYSTEMS AS ANTI-HIV AGENTS Institut Quimic De Sarria Cets (ES) 2009-09-16 — — EP claimed
US-20100022769-A1 NOVEL POLYNITROGENATED SYSTEMS AS ANTI-HIV AGENTS INSTITUT QUIMIC DE SARRIA CETS (ES) 2010-01-28 — — US disclosed
EP-2100890-A1 NOVEL POLYNITROGENATED SYSTEMS AS ANTI-HIV AGENTS Institut Quimic De Sarria Cets (ES) 2009-09-16 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022769-A1 NOVEL POLYNITROGENATED SYSTEMS AS ANTI-HIV AGENTS MSR1, CCR5, CD4 CYP2C19 830/4885CYP3A4 397/4885CYP2D6 310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback